权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Visualization of in vivo HIV-1 vaginal transmission in the presence and absence of PrEP

在存在和不存在 PrEP 的情况下体内 HIV-1 阴道传播的可视化

基本信息

批准号：
8845917
负责人：
Zandrea Ambrose
金额：
$ 65.82万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-11-01 至 2019-10-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8845917
关键词：
Address Adherence Affect Animal Model Anti-Retroviral Agents Biology Blood Bone Marrow Cells Clinical Trials Data Development Dose Drug Kinetics Drug resistance Failure Female Focal Infection Genital system HIV HIV-1 Health Personnel Human Imagery Imaging technology In Vitro Individual Infection Injectable Intramuscular Kinetics Lead Liver Macaca Methods Modeling Mus Mutation Oral Patients Pharmaceutical Preparations Plasma Process Prophylactic treatment Regimen Reporter Resistance Resistance development Resistance profile Reverse Transcriptase Inhibitors Route SIV System Technology Tenofovir Therapeutic Thymus Gland Time Tissues Treatment outcome Vaccines Variant Viral Virus Woman antiretroviral therapy clinically relevant comparative efficacy high risk imaging system in vivo innovation innovative technologies macrophage mouse model mutant nanoparticle non-nucleoside reverse transcriptase inhibitors nonhuman primate novel public health relevance resistance mutation simian human immunodeficiency virus success transmission process truvada vaginal transmission

项目摘要

DESCRIPTION (provided by applicant): In the absence of an effective vaccine, administration of antiretroviral drugs prior to human immunodeficiency virus type 1 (HIV-1) exposure (pre-exposure prophylaxis or PrEP) may be a reliable method to protect high-risk HIV-negative individuals from infection. Daily oral tenofovir and FTC (Truvada) is currently approved for use as PrEP in high-risk individuals but has had limited success in human clinical trials to date, mainly due to adherence issues. Rilpivirine (RPV) is the most recent reverse transcriptase inhibitor approved for antiretroviral therapy (ART) for HIV-1. Drug-resistant mutations detected in patients failing RPV-containing regimens conferred mainly low-level resistance to RPV and RPV is active against most mutants selected by other drugs. RPV has been formulated into injectable long-acting nanoparticles (RPV-LA) for use as long-lasting PrEP to be administered by healthcare providers. Development of resistance or transmission of RPV-resistant variants during PrEP has not been previously addressed, particularly their impact on subsequent ART. A case has recently been described of a woman who became HIV-1-infected during RPV-LA treatment and subsequently developed RPV-resistant virus in the presence of sub-therapeutic plasma RPV concentration. We propose to investigate vaginal transmission of wild-type (WT) HIV-1 and drug-resistant variants in the presence and absence of therapeutic and subtherapeutic concentrations of RPV-LA PrEP or Truvada, using a novel animal model that will also allow us to investigate the dynamics of infection and dissemination in the female genital tract in real-time. Using an innovative new reporter virus system and a well-characterized humanized mouse model, we hypothesize that a prevalent HIV-1 mutant resistant to both RPV and Truvada (E138K/M184I) will be transmitted in the absence of drug and in the presence of Truvada PrEP, but will lead to an abortive infection of local CD4+ target cells in the genital trac in the presence of therapeutic RPV-LA concentrations. However, transmission or development of drug-resistant HIV-1 will lead to faster virologic failure during subsequent ART.

描述(由申请人提供)：在缺乏有效疫苗的情况下，在人类免疫缺陷病毒1型(HIV-1)暴露之前给予抗逆转录病毒药物(暴露前预防或PrEP)可能是保护高危HIV阴性个人免受感染的可靠方法。每日口服替诺福韦和FTC(特鲁瓦达)目前被批准用于高危个体的PrEP，但迄今为止在人体临床试验中取得的成功有限，主要是由于依从性问题。利培韦林(RPV)是最近被批准用于HIV-1抗逆转录病毒治疗(ART)的逆转录酶抑制剂。在失败的含RPV方案的患者中检测到的耐药突变主要是对RPV的低水平耐药性，RPV对其他药物选择的大多数突变都是有效的。RPV已被配制成可注射长效纳米粒(RPV-LA)，用于由医疗保健提供者管理的长效PrEP。在PrEP期间RPV耐药变体的发展或传播以前没有被解决，特别是它们对后续技术的影响。最近描述了一例妇女在RPV-LA治疗期间感染艾滋病毒-1，随后在存在亚治疗性血浆RPV浓度的情况下发展出RPV耐药病毒。我们建议使用一种新的动物模型，在存在和不存在治疗性和亚治疗性浓度的RPV-LA PrEP或Truvada的情况下，研究野生型(WT)HIV-1和耐药变异株的阴道传播，这也将使我们能够实时调查女性生殖道中感染和传播的动态。使用创新的新报告病毒系统和特征良好的人源化小鼠模型，我们假设，对RPV和Truvada都具有耐药性的流行HIV-1突变株(E138K/M184I)将在没有药物和Truvada PrEP存在的情况下传播，但在治疗性RPV-LA浓度存在的情况下，将导致生殖器trac中局部CD4+靶细胞的流产感染。然而，耐药HIV-1的传播或发展将导致在随后的ART中更快的病毒学失败。